nach oben

International Journal of Diabetes in Developing Countries

Erschienen in:

01.12.2014 | Editorial

Visible signs of insulin resistance: opportunities lost

verfasst von: G. Nagamani, P. G. Sundararaman, G. R. Sridhar

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Excerpt

The hope of a young physician’s call for “Small fevers are gratefully accepted” can be matched by the despair of the senior physician’s “If only diabetes were a little more symptomatic.” The senior physicians’ hopes can be fulfilled to a certain extent—if only. …

Casarini L, Brigante G. The polycystic ovary syndrome evolutionary paradox: a genome-wide association studies-based, in silico, evolutionary explanation. J Clin Endocrnol Metab. 2014;99:E2412–20.CrossRef

Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertility Soc J. 2011;16:19–37.CrossRef

Ganie MA, Nisar S. Current perspectives of polycystic ovary syndrome (PCOS). JIMSA. 2008;21:161–5.

Conway G, Dewailly D, Kandarakis ED, Morreale HFE, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171:1–29.CrossRef

Sridhar GR, Lakshmi G. Sleep and obesity. J Gen Med. 2009;21:54–6.

Buxton OM, Cain SW, O’Connor SP, Porter JH, Duffy JF, Wang W, et al. Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med. 2012;4:129ra–43.

Sridhar GR, Venkata P. Sleep and body weight in diabetes mellitus: a large retrospective analysis from south India. Diab Res Clin Pract. 2006;72:209–11.CrossRef

Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes. Diabetes. 2012;61:2369–74.PubMedCentralPubMedCrossRef

Morgan CL, Jones SJ, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab. 2012. doi:10.1210/jc.2012-1690.

10.

Salley KES, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Position statement: glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92:4546–56.PubMedCrossRef

11.

Ehrmann DA, Kasza K, Azziz R, Legro S, Ghazzi MN, for the PCOS/Troglitazone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:66–71.PubMedCrossRef

12.

Majumdar A, Singh TA. Comparison of clinical features and health manifestations in lean vs obese Indian women with polycystic ovarian syndrome. J Hum Reprod Sci 2009;2:doi 10.4103/0974-1208.51336

13.

Gill H, Tiwari P, Dabadghao P. Prevalence of polycystic ovary syndrome in young women from North India: a community-based study. Indian J Endocrinol Metab. 2012;16 Suppl 2:S389–92.PubMedCentralPubMed

14.

Zargar AH, Gupta K, Wani AI, Masoodi S, Bashir MI, Laway BA, et al. Prevalence of ultrasonography proved polycystic ovaries in North Indian women with type 2 diabetes mellitus. Reprod Biol Endocrinol. 2005;3:35.PubMedCentralPubMedCrossRef

15.

Ramanand SJ, Ghongane BB, Ramanand JB, Patwardhan MH, Ghanghas RR, Jain SS. Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocrinol Metab. 2013;17:138–45.PubMedCentralPubMedCrossRef

16.

Sundararaman PG, Manomani R, Sridhar GR, Sridhar V, Sundaravalli A, Umachander M. Risk of atherosclerosis in women with polycystic ovary syndrome: a study from south India. Metab Syndr el Dis. 2004;1:271–5.CrossRef

17.

Moghetti P, Tosi F, Bonin C, Sarra DD, Fiers T, Kaufman JM, et al. Divergence in insulin resistance in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E628–37.PubMedCrossRef

18.

Jie Q. Pay more attention to ethnic differences in polycystic ovary syndrome phenotypic expression. Chinese Med J. 2013;126:2003–6.

19.

Ganie MA, Marwaha RK, Aggarwal R, Singh S. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case–control study. Eur J Endocrinol. 2010;162:1117–22.PubMedCrossRef

20.

Ganie MA, Laway BA, Wani TA, Zargar MA, Nisar S, Ahamed F, et al. Association of subclinical hypothyroidism and phenotype, insulin resistance, and lipid parameters in young women with polycystic ovary syndrome. Fertile Steril. 2011;95:2039–43.CrossRef

21.

Sridhar GR, Nagamani G. Association of polycystic ovary syndrome with anticonvulsant use: a case report. Metabolic Syndr Rel Disorders. 2006;4:215–7.CrossRef

22.

Sundararaman PG, Shweta, Sridhar GR. Psychosocial aspects of women with polycystic ovary syndrome from south India. J Assoc Physicians India. 2008;56:945–8.PubMed

23.

Sridhar GR, Madhu K. Stress in the cause and course of diabetes. Intl J Diab Dev Countries. 2001;21:112–20.

24.

Farrell K, Antoni M. Insulin resistance, obesity, inflammation and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2010;94:1565–74.PubMedCentralPubMedCrossRef

25.

Kaviprasanna S, Saikumar P, Alaguveni T. Insulin resistance as an independent risk factor for the development of dyslipidemia in polycystic ovarian syndrome. Adv Biol Res. 2014;8:53–6.

26.

Rajendra Prasad N, Bitla AR, Suchitra MM, Rajagopal G, Sachan A, Srinivasa Rao PVLN. A study on prevalence of abnormal glucose tolerance and correlation of insulin resistance with dyslipidemia in south-Indian women with polycystic ovary syndrome. Intl J Diab Dev Cntr 2014; 34: page numbers to be added

27.

Welt CK, Carmina E. Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab. 2013;98:4629–38.PubMedCentralPubMedCrossRef

28.

Chen Z-J, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55–60.PubMedCrossRef

29.

Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012;44:1020–5.PubMedCrossRef

30.

Casarini L, Brigante G. The polycystic ovary syndrome evolutionary paradox: a genome-wide association studies-based, in silico, evolutionary explanation. J Clin Endocrinol Metab. 2014;99:E2412–20.PubMedCrossRef

Titel: Visible signs of insulin resistance: opportunities lost
verfasst von: G. Nagamani
P. G. Sundararaman
G. R. Sridhar
Publikationsdatum: 01.12.2014
Verlag: Springer India
Erschienen in: International Journal of Diabetes in Developing Countries / Ausgabe 4/2014
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-014-0262-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Status of zinc and magnesium levels in type 2 diabetes mellitus and its relationship with glycemic status

A study on prevalence of abnormal glucose tolerance and correlation of insulin resistance with dyslipidemia in South-Indian women with polycystic ovary syndrome

A correlation study of CVD risk factors in Type 2 diabetics of Western Rajasthan

Assessment of thyroid dysfunction in the type 2 diabetic patients

Knowledge and awareness of diabetes amongst diabetes patients in Wardha region

Patients with type 1 diabetes transition from pediatric to adult care in Poland—an example from Silesia